Skin intrinsic fluorescence is associated with coronary artery disease in individuals with long duration of type 1 diabetes.

Conway BN, Aroda VR, Maynard JD, Matter N, Fernandez S, Ratner RE, Orchard TJ

The C allele of ATM rs11212617 does not associate with metformin response in the Diabetes Prevention Program.

Florez JC, Jablonski KA, Taylor A, Mather K, Horton E, White NH, Barrett-Connor E, Knowler WC, Shuldiner AR, Pollin TI, Diabetes Prevention Program Research Group

N-acetylserotonin and aging-associated cognitive impairment and depression.

Oxenkrug G, Ratner R

n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.

ORIGIN Trial Investigators, Bosch J, Gerstein HC, Dagenais GR, DĂ­az R, Dyal L, Jung H, Maggiono AP, Probstfield J, Ramachandran A, Riddle MC, RydĂŠn LE, Yusuf S

Basal insulin and cardiovascular and other outcomes in dysglycemia.

ORIGIN Trial Investigators, Gerstein HC, Bosch J, Dagenais GR, DĂ­az R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, RydĂŠn LE, Yusuf S

Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets.

DeVries JH, Bain SC, Rodbard HW, Seufert J, D'Alessio D, Thomsen AB, Zychma M, Rosenstock J, Liraglutide-Detemir Study Group

Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study.

Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE, Diabetes Prevention Program Research Group

A clinical trial to maintain glycemic control in youth with type 2 diabetes.

TODAY Study Group, Zeitler P, Hirst K, Pyle L, Linder B, Copeland K, Arslanian S, Cuttler L, Nathan DM, Tollefsen S, Wilfley D, Kaufman F

The American Diabetes Association diabetes research perspective.

Fonseca VA, Kirkman MS, Darsow T, Ratner RE

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR, American Diabetes Association (ADA), European Association for the Study of Diabetes (EASD)

The American Diabetes Association diabetes research perspective.

Fonseca VA, Kirkman MS, Darsow T, Ratner RE

Improved health status with insulin degludec compared with insulin glargine in people with type 1 diabetes.

Home PD, Meneghini L, Wendisch U, Ratner RE, Johansen T, Christensen TE, Jendle J, Roberts AP, Birkeland KI

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.

Heller S, Buse J, Fisher M, Garg S, Marre M, Merker L, Renard E, Russell-Jones D, Philotheou A, Francisco AM, Pei H, Bode B, BEGIN Basal-Bolus Type 1 Trial Investigators

Gender-based divergence of cardiovascular outcomes in asymptomatic patients with type 2 diabetes: results from the DIAD study.

Tandon S, Wackers FJ, Inzucchi SE, Bansal S, Staib LH, Chyun DA, Davey JA, Young LH, DIAD Investigators

The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS.

Diabetes Prevention Program Research Group